Content focuses on validation requirements, regulatory frameworks, and industry standards across regulated manufacturing sectors. It covers pharmaceutical, biopharmaceutical, medical device, 503B outsourcing facility, and cosmetic product manufacturing. Content compares how industry-specific requirements influence validation, qualification, quality systems, documentation, risk management, and inspection readiness throughout the product and system lifecycle.
The Quality Management System Regulation (QMSR) establishes the current U.S. quality-system requirements for medical device manufacturers. Effective February 2, 2026, the QMSR amended 21 CFR Part 820 and incorporated ISO 13485:2016 by reference as the principal quality-management framework for medical…
The Quality Management System Regulation (QMSR) and ISO 13485:2016 are now directly connected, but they are not interchangeable. Effective February 2, 2026, the QMSR amended 21 CFR Part 820 and incorporated ISO 13485:2016 by reference. Applicable ISO 13485 requirements therefore…
The Quality Management System Regulation (QMSR) became effective on February 2, 2026, and is the current regulatory framework governing quality management system requirements for medical device manufacturers in the United States. The QMSR amended 21 CFR Part 820 by incorporating…
21 CFR Parts 210 and 211 establish Current Good Manufacturing Practice requirements for manufacturing, processing, packing, and holding drug products in the United States. These legally enforceable requirements provide the regulatory foundation for controlling pharmaceutical facilities, equipment, materials, production processes,…
Regulatory validation requirements are central to maintaining control over biopharmaceutical manufacturing. Biological products are structurally complex, sensitive to manufacturing conditions, and frequently dependent on living cells or biological source materials. Product quality therefore cannot be assured through finished-product testing alone….
Section 503B outsourcing facilities are a distinct category of FDA-registered drug-compounding facilities. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), an outsourcing facility is a facility at one geographic location or address that compounds sterile drugs, elects to…
Cosmetic product manufacturing in the United States is regulated under the Federal Food, Drug, and Cosmetic Act (FD&C Act), as substantially amended by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Most cosmetic products and ingredients do not require…
FDA inspection readiness is the sustained ability of a regulated establishment to demonstrate that its operations comply with applicable statutory, regulatory, application, and procedural requirements. It depends on effective quality systems, controlled operations, reliable records, knowledgeable personnel, and timely correction…